陆小云，女，博士，研究员，广东省杰出青年基金获得者，863青年科学家项目获得者，广州市珠江新星。2005年6月毕业于中国药科大学制药工程专业，获学士学位；2010年6月毕业于中国药科大学药物化学专业，获理学博士学位；2010年7月-2016年2月在中国科学院广州生物医药与健康研究院从事科研工作，2012年1月被聘为副研究员；2016年3月加入暨南大学药学院，从事教学科研工作。

  从事创新药物先导化合物的发现研究。主要瞄准肺部疾病（肺癌和结核病等）临床耐药问题，设计和合成具有重要生物学功能和良好成药性的先导化合物，为创新药物开发奠定基础。现主持863青年科学家项目，广东省杰出青年项目，广东省人才和广州市珠江新星等研究课题。已在Angew. Chem. Int. Ed.和J. Med. Chem 等重要专业期刊发表第一作者或通讯作者SCI论文30余篇，申请发明专利20余项（授权10项，PCT 4项），部分专利已实现转移转化。曾获中国药学会-施维雅药物化学奖，中科院卢嘉锡青人才奖等奖项。

主要研究方向: 

 1. 新型抗肺癌成药性先导化合物的研究   

 2. 克服临床耐药的新型抗结核药物研究

 3. 其他新型激酶类抑制剂的设计研究

近五年内发表的代表性论文：

1.       Qiujue Xun*, Zhang Zhang*, JinfengLuo,  LingjiangTong, Minghao Huang, zhen Wang, Jian Zou, Yong Xu, Hua Xie, Zheng-Chao Tu, Xiaoyun Lu*, Ke Ding*.Design, Synthesis and Structure-Activity Relationship Study of 2-Oxo-3, 4-dihydropyrimido[4, 5-d] Pyrimidines as New Colony Stimulating Factor-1 Receptor (CSF1R) Kinase Inhibitors. J. Med. Chem. 2018, doi: 10.1021/acs.jmedchem.7b01612

2.       Xiaoyun Lu*, Lei Yu, ZhangZhang, Xiaomei Ren, Jeff BSmaill, KeDing*. Targeting EGFRL858R/T790M and EGFRL858R/T790M/C797S resistance mutations in NSCLC: Current developments in medicinal chemistry. Med. Res. Rev. 2018, doi: 10.1002/med.21488.

3.       Yu Chang#, Xiaoyun Lu#, Marthiandam Asokan Shibu#, YiBo Dai#, Jinfeng Luo, Yan Zhang, Yingjun Li, Peng Zhao, Zhang Zhang, Yong Xu, Zheng Chao Tu, Qingwen Zhang*, Caihong Yun*, Chih.-Yang Huang*, and Ke Ding*. Structure-Based Design of N-(3-((1H-pyrazolo[3,4-b]pyridin-5-yl)ethynyl) Benzenesulfonamides as Selective Leucine- Zipper and Sterile-α Motif Kinase (ZAK) Inhibitors. J. Med. Chem.2017, 60(13):5927-5932.

4.       Cheng Mo, Zhang Zhang, Christopher P. Guise, Xueqiang Li, Jinfeng Luo†, Zhengchao Tu, Yong Xu, Adam V. Patterson, Jeff B. Smaill*, Xiaomei Ren*, Xiaoyun Lu*, and Ke Ding*. 2-Aminopyrimidine Derivatives as New Selective Fibroblast Growth Factor Receptor 4 (FGFR4) Inhibitors. ACS Med. Chem. Lett., 2017. 8, 543-548.

5.       Zhen Wang#, Yali Zhang#, Sergio G. Bartual, Jinfeng Luo, Tingting Xu, Wenting Du, Qiuju Xun, Zhengchao Tu, Rolf A. Brekken, Xiaomei Ren, Alex N. Bullock,* Guang Liang,* Xiaoyun Lu,* and Ke Ding*.Tetrahydroisoquinoline-7-carboxamide Derivatives as New Selective Discoidin Domain Receptor 1 (DDR1) Inhibitors. ACS Med. Chem. Lett. 2017, 8 (3), 327-332

6.       Lei Yu, Minhao Huang, Tianfeng Xu, Linjiang Tong, Xiao-e Yan, Zhang Zhang, Yong Xu, Caihong Yun, Hua Xie*, Ke Ding*, Xiaoyun Lu*. A structure-guided optimization of pyrido[2,3-d]pyrimidin-7-ones as selective inhibitors of EGFRL858R/T790M mutant with improved pharmacokinetic properties. Eur J Med Chem., 2017,126, 1107-1117.

7.       Xiaoyun Lu#*, Zhang Zhang#, Xiaomei Ren, Deping Wang, Ke Ding*. Synthesis and identification of GZD856 as an orally bioavailable Bcr-AblT315I inhibitor overcoming acquired imatinib resistance. J. Enzy. Inhib. Med. Chem., 2017, 32, 331-336.

8.       Xiaoyun Lu,*  Xianglong Hu,  Zhiyong Liu, Tianyu Zhang, Ruibing Wang, Baojie Wan,  Scott G. Franzblaud  and  Qidong You*. Benzylsulfanyl benzo-heterocycle amides and hydrazones as new agents against drug-susceptible and resistant Mycobacterium tuberculosis. Med. Chem. Comm., 2017, 8, 1303-1306.

9.       Xiaoyun Lu#*, Jian Tang#, Shengyang Cui, Baojie Wan, Scott G. Franzblauc, Tianyu Zhang, Xiantao Zhang, Ke Ding. Pyrazolo[1,5-a]pyridine-3-carboxamide hybrids: Design, synthesis and evaluation of anti-tubercular activity. Euro. J. Med. Chem., 2017,125, 41-48.

10.   Yu Chang, Qingwen Zhang, Zhengqiu Li, Ke Ding *, and Xiaoyun Lu*. Leucine-Zipper and Sterile-α Motif Kinase (ZAK): A Potential target for Drug Discovery. Cur. Med. Chem., 2016, 23, 3801-3812.

电话： 020-85223259

联系方式: E-mail: luxy2016@jnu.edu.cn